We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Meningitis Bacteriana Aguda: Análisis Demográfico de Mortalidad en Chile entre los años 2018-2022.
- Authors
Quiroz, M.; Bórquez, C.; Gómez, C.; García, L.; Elfernan, I.
- Abstract
Acute bacterial meningitis (ABM) is an inflammation of the subarachnoid space, with Streptococcus pneumoniae being the main cause, and a global mortality rate of 20%. In Chile, the incidence in 2019 was 4.2 per 100,000 inhabitants, with the highest incidence in the Metropolitan Region. Objective: Calculate the mortality rate (MR) due to ABM in Chile between the years 2018-2022. Methodology: descriptive, ecological study about deaths by ABM, period 2018-2022 in Chile (n=170) according to sex, age group (AG) and region. Data obtained from Departamento de Estadística e Información de Salud. Descriptive statistics were used, MR calculation and Swaroop Index (SI). Results: A MR of 0.17/100,000 inhabitants was calculated for the period. 2022 had the highest MR with 0.29. The male sex obtained a rate of 0.21. AG between 80 and over presented the highest MR with 1.09/100,000 inhabitants. SI was led by III region, with 100%, followed by IV, X regions and XVI with 85.71%. Discussion: The decrease in MR between 2020 and 2021 could be related to the SARS-CoV-2 outbreak. The MR reached its highest value in the group of 80 years and over, which can be attributed to a lower physiological reserve, a greater presence of comorbidities and polypharmacy. An IS close to 90% was registered in regions X, XVI and IV, coinciding with a lower overcrowding index, a risk factor for the development of the disease. In conclusion, we suggest investigating risk factors and improving early detection of the disease.
- Subjects
DISEASE risk factors; BACTERIAL meningitis; SUBARACHNOID space; EARLY diagnosis; STREPTOCOCCUS pneumoniae
- Publication
Revista ANACEM, 2024, Vol 18, Issue 1, p41
- ISSN
0718-5308
- Publication type
Academic Journal
- DOI
10.70536/RevANACEM/V18N1-311024005